Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osteologix, a specialty biopharmaceutical company, has reported that the European Patent Office has upheld the validity of the company's European patent that covers claims linked to its osteoporosis drug.
Subscribe to our email newsletter
This patent offers protection for the use of NB S101(strontium malonate) for the treatment of osteoporosis and related conditions while confirming that the innovative product, NB S101, demonstrated a significant increase in bioavailability over the EMEA approved Protelos (strontium ranelate).
The European Patent Office originally issued the patent in October 2006, with an expiration date in May 2024. In July 2007, Intellectual Property Services (IPS) of Paris, France, filed notice of opposition against the Osteologix European patent, requesting revocation of the patent in its entirety. In March 2009, the opposition division upheld the Osteologix patent without changes and rejected IPS’s request to revoke the Osteologix patent.